Japan-based Kowa Company, Ltd. announced on June 30 that the US FDA granted Breakthrough Therapy Designation (BTD) to K-808 (pemafibrate), a selective peroxisome proliferator-activated receptor alpha (PPARα) modulator (SPPARMα), for the treatment of primary biliary cholangitis (PBC). The designation, received on June 11, was based on preliminary data from the ongoing Phase II clinical trial K-808-2.01, which the company reported demonstrated a statistically significant reduction in alkaline phosphatase (ALP) levels — a validated surrogate endpoint for disease progression in PBC. The designation positions Kowa’s pemafibrate BTD as the first formal US regulatory recognition for the molecule, which has been approved in Japan since 2018 under the brand name Parmodia Tablets for hyperlipidemia.
Breakthrough Therapy Designation provides intensive guidance from senior FDA staff and all the benefits of Fast Track Designation, including eligibility for rolling review. Kowa has not previously disclosed any other FDA expedited designations for pemafibrate in PBC.
Kowa is developing K-808 for two patient populations: adults with an inadequate response to ursodeoxycholic acid (UDCA), the established first-line therapy for PBC, in whom pemafibrate would be used as a combination partner; and patients unable to tolerate UDCA, for whom monotherapy is intended. The company has stated its goal is global approval, including in the US and Japan.
PBC is a chronic, progressive autoimmune cholestatic liver disease characterised by immune-mediated destruction of small intrahepatic bile ducts. As bile acid accumulation drives hepatic inflammation and fibrosis, the disease can progress to cirrhosis and liver failure. It primarily affects women, and its rare disease classification reflects a global prevalence estimated at approximately 100,000 patients in the US. ALP remains the most widely used biochemical marker of cholestasis and disease activity, and its reduction — particularly below 1.67 times the upper limit of normal — is a regulatory-accepted surrogate for improved long-term outcomes.
Pemafibrate acts as a selective PPARα modulator, distinguishing it from non-selective fibrate-class drugs. By activating the nuclear receptor PPARα in hepatocytes, it regulates gene expression involved in lipid and bile acid metabolism. In the context of PBC, the proposed mechanisms include inhibition of bile acid synthesis, anti-inflammatory effects mediated through PPARα activation, and micellisation of hydrophobic bile acids — each of which could reduce hepatic bile acid load and attenuate cholestatic injury.